EUVIMEDEUVIMED entdecken
Crossref

A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics

Xiangcheng Zhao, Peng Yan, Hailong Zhang, Wenhu Zhou, Jinsong Ding

European Journal of Pharmaceutics and Biopharmaceutics · 2025

DOI: 10.1016/j.ejpb.2025.114633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025. Verfasst von Xiangcheng Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China. Hauptthemen laut MEDLINE: Levodopa, Carbidopa, Antiparkinson Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The narrow absorption window of levodopa and the significant impact of peripheral decarboxylase are the most limiting factors in maintaining prolonged and smooth plasma concentration in patients with Parkinson's disease (PD). Therefore, this study aims to design a novel gastroretentive carbidopa-levodopa three-layer tablet, which consists of an expansion layer, an immediate-release layer, and a sustained-release layer. The expansion layer rapidly expanded with sufficient structural strength and stayed in the beagle's stomach for more than 10 h, delineating excellent gastric retention effects. The immediate-release layer quickly released the drug and the sustained-release layer maintained a stable drug concentration. Importantly, pharmacokinetic data obtained under fed conditions demonstrated that the duration of efficacy of the three-layer tablets was significantly superior to that of the commercially available product Sinemet® CR, with effective levodopa blood levels remaining for up to 12 h. This is expected to offer more convenient clinical medication options for patients with PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaCarbidopaAntiparkinson AgentsDrug CombinationsTabletsDelayed-Action PreparationsAnimalsMaleParkinson DiseaseDrug LiberationHumans

Stichwörter der Autor:innen

CarbidopaGastric retentionLevodopaPharmacokineticsSustained releaseThree-layer tablet

Substanzen

LevodopaCarbidopacarbidopa, levodopa drug combinationDrug CombinationsTabletsAntiparkinson AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China; Changsha Jingyi Pharmaceutical Technology Co., LTD., Changsha, Hunan 410006, China.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China. Electronic address: zhouwenhuyaoji@163.com.
  • Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China. Electronic address: dingjs0221@csu.edu.cn.

Zitieren

APA

Zhao, X., Yan, P., Zhang, H., Zhou, W., & Ding, J. (2025). A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114633

Vancouver

Zhao X, Yan P, Zhang H, Zhou W, Ding J. A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics. European Journal of Pharmaceutics and Biopharmaceutics. 2025. doi:10.1016/j.ejpb.2025.114633

BibTeX
@article{Zhao2025,
  author = {Zhao, Xiangcheng and Yan, Peng and Zhang, Hailong and Zhou, Wenhu and Ding, Jinsong},
  title = {A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2025},
  doi = {10.1016/j.ejpb.2025.114633}
}
Kostenlos starten →